June 12, 2007 Male pattern hair loss (MPHL) is a condition that affects as many as 50 percent of men by the age of fifty, but according to a new study, baldness may soon be a treatable condition.
Using pairs of identical twins, the study assessed the efficacy of dutasteride, a particular enzyme inhibitor, as a means of reducing hair loss and encouraging new growth, finding it to be an effective means of combating baldness.
In the study, one of each pair of twins was given 0.5 mg/day of the medication, the other receiving a placebo, with the results monitored over the course of a year. After both 6 and 12-month intervals, hair loss was found to not only have been halted in twins using dutasteride, but hair growth was actively improved. The rate of growth increased between the 6 and 12-month evaluations, while hair loss continued steadily in the placebo group.
MPHL is thought to be genetically controlled. As identical twins share the same genetic code, the study provides particularly convincing evidence of the efficacy of dutasteride.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.